Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
NT

NASDAQ · NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

Healthcare · Biotechnology

$4.68

Up+$0.12 (+2.52%)

Updated Aug 23, 2026, 8:26 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
181.31M
P/E ratio
-3.28
Dividend yield
0.00%
52-week range
$3.01 – $12.99
Volume
167.74K
Avg. volume
77.82K

Price performance

NTHI price history

1M range · 20 trading sessions · Daily adjusted prices

NTHI closed at $4.68 after 20 trading sessions, up 35.90% for the selected period.

Last close
$4.68
Period change
+35.90%
Period low
$3.21
Period high
$5.53
Daily close
View OHLC price history
NTHI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$4.61$4.8899$4.39$4.675167.74K
Aug 20, 2026$4.56$4.7102$4.3183$4.56190.28K
Aug 19, 2026$5.53$5.70$4.54$4.63400.19K
Aug 18, 2026$4.87$5.82$4.85$5.53319.75K
Aug 17, 2026$4.17$5.00$3.775$4.91386.48K
Aug 14, 2026$3.22$4.3277$3.18$4.22646.95K
Aug 13, 2026$3.51$3.65$3.13$3.21388.48K
Aug 12, 2026$4.49$4.74$3.30$3.461.11M
Aug 11, 2026$3.78$4.51$3.49$4.351.07M
Aug 10, 2026$3.47$3.61$3.31$3.50209.8K
Aug 7, 2026$3.50$3.62$3.47$3.5051.1K
Aug 6, 2026$3.50$3.5639$3.44$3.5032.49K
Aug 5, 2026$3.43$3.5686$3.43$3.5017.64K
Aug 4, 2026$3.50$3.57$3.43$3.4357.53K
Aug 3, 2026$3.44$3.63$3.40$3.4639.82K
Jul 31, 2026$3.45$3.704$3.35$3.4963.36K
Jul 30, 2026$3.47$3.55$3.3501$3.4929.38K
Jul 29, 2026$3.50$3.54$3.425$3.5021.14K
Jul 28, 2026$3.45$3.6228$3.45$3.4952.89K
Jul 27, 2026$3.43$3.52$3.34$3.4419.61K

Latest NTHI news

The latest Smart Investors Daily articles mentioning NTHI.

Stock researchCompany · Overview

NTHI research

Overview

Company profile and research snapshot.

Company profile

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NTHI recent ratings
DateFirmRatingTarget
May 26, 2026BTIGBuy—
May 19, 2026Alliance Global PartnersBuy—
May 18, 2026Maxim GroupBuy—
Apr 24, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 13, 2026

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). 2Q26 meaningfully improves the clinical setup for NTHI, with NEO100 delivering a positive Phase 2a readout and NEO212 gaining regulatory clarity. NEO100 met its primary endpoint with six-month PFS of 48.9% by RANO 2.0 using Kaplan-Meier estimation versus a pre-specified 20% benchmark...

Yahoo · Aug 12, 2026

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 monthsHouston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate compared with a 20% historical benchmark.The result was nearly 2.5.

Yahoo · Aug 12, 2026

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% of patients alive at six months — Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days — No major toxicities reported across the coho

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By